Investing
Ophthotech, Alexion Tumble into Monday's 52-Week Low Club
Published:
Last Updated:
December 12, 2016: Here are four stocks trading with relatively heavy volume among 28 equities making new 52-week lows in Monday’s session. On the NYSE, decliners led advancers by nearly 2 to 1 and on the Nasdaq decliners led advancers by more than 2 to 1.
Ophthotech Corp. (NASDAQ: OPHT) dropped about 86% on Monday to post a new 52-week low of $5.25 after closing at $38.77 on Friday. The stock’s 52-week high is $80.00. Volume of about about 46 million shares was nearly 46 times the daily average of 1 million. The company announced a failed late-stage clinical trial.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) dropped about 16.9% on Monday to post a new 52-week low of $109.80 against a 52-week high of $193.45 and a Friday close of $132.07. Volume of around 12.5 million was almost 6 times the daily average of around 2.2 million. The company’s CEO and CFO left the company.
FitBit Inc. (NYSE: FIT) lost 2.8% Monday to post a new 52-week low of $7.60 after closing Friday at $7.82. The 52-week high is $30.96. Volume of around 8 million was about 20% below the daily average of around 10 million shares traded. The company had no specific news Monday.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) dropped about 7.4% on Monday to post a new 52-week low of $1.25 after closing at $1.35 on Friday. The stock’s 52-week high is $8.22. Volume was about 25% above the daily average of around 1.6 million shares. The company had no specific news.
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.